STUDY: Long term mask use breeds microbes that infiltrate the lungs and contribute to advanced stage lung cancer
(Natural News) A new study finds that cultivation and enrichment of microbes on the face can infiltrate the lungs through unconscious aspirations and cause inflammatory responses and advanced stage lung cancer. The nose and the mouth were designed to take in oxygen without strain, uninhibited. The oxygen travels down the trachea and splits off into... (Source: NaturalNews.com)
Source: NaturalNews.com - January 15, 2021 Category: Consumer Health News Source Type: news

Behaviors surrounding oral sex may increase HPV-Related cancer risk
(Johns Hopkins Medicine) A wide breadth of behaviors surrounding oral sex may affect the risk of oral HPV infection and of a virus-associated head and neck cancer that can be spread through this route, a new study led by researchers at the Johns Hopkins Kimmel Cancer Center suggests. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 14, 2021 Category: International Medicine & Public Health Source Type: news

Esophageal cancer patients show abundance of oral pathogens
(Tokyo Medical and Dental University) DNA from various oral bacterial pathogens has been found in tumors from esophageal cancer patients. Researchers led by Tokyo Medical and Dental University (TMDU) examined bacterial pathogens in plaque and saliva from esophageal cancer patients, determining that a prevalence of three species in particular, along with alcohol consumption, is associated with a high risk of esophageal cancer. Screening of oral pathogens could therefore be used for early disease detection. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 14, 2021 Category: Cancer & Oncology Source Type: news

Janssen to Highlight Commitment to Lung Cancer Science and Innovation with Eight Data Presentations at the International Association for the Study of Lung Cancer ’s 2020 World Conference on Lung Cancer
January 12, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that eight company-sponsored presentations, including two oral presentations, will be featured at the International Association for the Study of Lung Cancer’s (IASLC) 2020 World Conference on Lung Cancer (WCLC) Singapore taking place virtually January 28-31, 2021. The presentations include updated data from the Phase 1 CHRYSALIS study (NCT02609776) evaluating amivantamab in patients with NSCLC and EGFR exon 20 insertion mutations and two studies that characterize the high unmet need and lack of stand...
Source: Johnson and Johnson - January 13, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Study Outlines Role of Oral Sex in Rare Throat, Mouth Cancers
  TUESDAY, Jan. 12, 2021 -- People who began having oral sex at a young age or at greater " intensity " may face an increased risk of a type of throat cancer, a new study finds. The study, published online Jan. 11 in the journal Cancer, focused... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 12, 2021 Category: General Medicine Source Type: news

Oral sex frequency, number of partners linked to HPV-related cancer risk in study
Having more than 10 oral sex partners over a lifetime quadruples a person's risk for human papillomavirus-related mouth and throat cancer, a study published Monday by the journal Cancer found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - January 11, 2021 Category: Consumer Health News Source Type: news

Toxins In Marijuana Smoke May Be Harmful To Health, Dana-Farber Study Finds
(CNN) — Smoking weed may expose you to the same type of toxic chemicals found in tobacco smoke, a new study finds. People who only smoked marijuana had higher blood and urine levels of several smoke-related toxins such as naphthalene, acrylamide and acrylonitrile than nonsmokers, according to the study published Monday in the journal EClinicalMedicine. Naphthalene is associated with anemia, liver and neurological damage, while acrylamide and acrylonitrile have been associated with cancer and other health issues. “Marijuana use is on the rise in the United States with a growing number of states legalizing it for...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - January 11, 2021 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health CNN Dana Farber Cancer Institute Marijuana Source Type: news

HPV Throat Cancer and Oral Sex at Younger Age, Multiple Partners HPV Throat Cancer and Oral Sex at Younger Age, Multiple Partners
Engaging in oral sex at a younger age and having more partners in a shorter period were associated with higher risks of developing human papillomavirus (HPV)-related oropharyngeal cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 11, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Timing, Intensity of Oral Sex Are Risk Factors for HPV-OPC
MONDAY, Jan. 11, 2021 -- In addition to number of oral sex partners, timing and intensity of oral sex are independent risk factors for human papillomavirus-related oropharyngeal cancer (HPV-OPC), according to a study published online Jan. 11 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 11, 2021 Category: Pharmaceuticals Source Type: news

mRNA Technology Gave Us the First COVID-19 Vaccines. It Could Also Upend the Drug Industry
“No!” The doctor snapped. “Look at me!” I had been staring her in the eyes, as she had ordered, but when a doctor on my other side began jabbing me with a needle, I started to turn my head. “Don’t look at it,” the first doctor said. I obeyed. This was in early August in New Orleans, where I had signed up to be a participant in the clinical trial for the Pfizer-BioNTech COVID-19 vaccine. It was a blind study, which meant I was not supposed to know whether I had gotten the placebo or the real vaccine. I asked the doctor if I would really been able to tell by looking at the syringe. &...
Source: TIME: Health - January 11, 2021 Category: Consumer Health News Authors: Walter Isaacson Tags: Uncategorized COVID-19 feature Magazine Source Type: news

mRNA Technology Gave Us the First COVID-19 Vaccines. It Could Also Upend the Drug Industry
“No!” The doctor snapped. “Look at me!” I had been staring her in the eyes, as she had ordered, but when a doctor on my other side began jabbing me with a needle, I started to turn my head. “Don’t look at it,” the first doctor said. I obeyed. This was in early August in New Orleans, where I had signed up to be a participant in the clinical trial for the Pfizer-BioNTech COVID-19 vaccine. It was a blind study, which meant I was not supposed to know whether I had gotten the placebo or the real vaccine. I asked the doctor if I would really been able to tell by looking at the syringe. &...
Source: TIME: Science - January 11, 2021 Category: Science Authors: Walter Isaacson Tags: Uncategorized COVID-19 feature Magazine Source Type: news

Timing and intensity of oral sex may affect risk of oropharyngeal cancer
(Wiley) Human papillomavirus (HPV) can infect the mouth and throat to cause cancers of the oropharynx. A new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society, has found that having more than 10 prior oral sex partners was associated with a 4.3-times greater likelihood of having HPV-related oropharyngeal cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 11, 2021 Category: International Medicine & Public Health Source Type: news

Oral Contraceptives Tied to Lower Risk for Certain Cancers
The drugs may increase the risk of breast cancer, but may lower the risk of ovarian and endometrial cancers. (Source: NYT Health)
Source: NYT Health - January 5, 2021 Category: Consumer Health News Authors: Nicholas Bakalar Tags: Ovarian Cancer Breast Cancer Women and Girls Deaths (Fatalities) Birth Control and Family Planning Source Type: news

Researchers aim AI at rising oral cancers with $3.3M grant from National Cancer Institute
(Case Western Reserve University) Researchers at Case Western Reserve University and partners in the United States and India are applying artificial intelligence (AI) to help physicians customize treatments for patients with the most common oral cancer, known as squamous cell carcinomas. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 5, 2021 Category: Cancer & Oncology Source Type: news

Jaw Osteonecrosis Tied to Treatment for Bone Metastases
Cancer type, oral health, and frequency of dosing for zoledronic acid linked to risk for osteonecrosis of the jaw (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 4, 2021 Category: Cancer & Oncology Tags: Oncology, Orthopedics, Pharmacy, Journal, Source Type: news

Mouth Bacteria Linked to Lung Cancer Risk in Never Smokers Mouth Bacteria Linked to Lung Cancer Risk in Never Smokers
The type and abundance of bacteria found in the mouth may be associated with lung-cancer risk in people who have never smoked, according a new study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 4, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Mouth cancer symptoms: When's the last time you looked into your mouth? Signs of cancer
MOUTH cancer can be deadly; one person dies of the disease every three hours, confirmed the Mouth Cancer Foundation. When's the last time you looked inside of your mouth? It could be harbouring signs of cancer. (Source: Daily Express - Health)
Source: Daily Express - Health - January 2, 2021 Category: Consumer Health News Source Type: news

Highlights in Metastatic Breast Cancer From SABCS 2020 Highlights in Metastatic Breast Cancer From SABCS 2020
From SABCS 2020, Dr Harold Burstein reports on advances for patients with HER2- metastatic breast cancer, including updates on immunotherapy and promising results for a novel oral taxane.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 30, 2020 Category: Consumer Health News Tags: Hematology-Oncology ReCAP Source Type: news

Why Do We Dream? A New Theory on How It Protects Our Brains
When he was two years old, Ben stopped seeing out of his left eye. His mother took him to the doctor and soon discovered he had retinal cancer in both eyes. After chemotherapy and radiation failed, surgeons removed both his eyes. For Ben, vision was gone forever. But by the time he was seven years old, he had devised a technique for decoding the world around him: he clicked with his mouth and listened for the returning echoes. This method enabled Ben to determine the locations of open doorways, people, parked cars, garbage cans, and so on. He was echolocating: bouncing his sound waves off objects in the environment and cat...
Source: TIME: Science - December 29, 2020 Category: Science Authors: David Eagleman and Don Vaughn Tags: Uncategorized Source Type: news

With potential $4B Pfizer deal, 'upside-down' Peninsula biotech on hunt for more drugs
Myovant Sciences Ltd. will use the financial muscle generated by a potential $4.2 billion deal with drug giant Pfizer Inc. to beef up its pipeline of cancer and women's health drugs. The Pfizer compact, disclosed Monday, centers on Brisbane-based Myovant's potential blockbuster drug relugolix, which won Food and Drug Administration approval this month as the first oral hormone therapy for men with advanced prostate cancer. Myovant's stock climbed as high as $30.90 per share M onday — a new 52-week… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 28, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

With potential $4B Pfizer deal, 'upside-down' Peninsula biotech on hunt for more drugs
Myovant Sciences Ltd. will use the financial muscle generated by a potential $4.2 billion deal with drug giant Pfizer Inc. to beef up its pipeline of cancer and women's health drugs. The Pfizer compact, disclosed Monday, centers on Brisbane-based Myovant's potential blockbuster drug relugolix, which won Food and Drug Administration approval this month as the first oral hormone therapy for men with advanced prostate cancer. Myovant's stock climbed as high as $30.90 per share M onday — a new 52-week… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 28, 2020 Category: American Health Authors: Ron Leuty Source Type: news

With potential $4 billion Pfizer deal, 'upside-down' Peninsula biotech on hunt for more drugs
Myovant Sciences Ltd. will use the financial muscle generated by a potential $4.2 billion deal with drug giant Pfizer Inc. to beef up its pipeline of cancer and women's health drugs. The Pfizer compact, disclosed Monday, centers on Brisbane-based Myovant's potential blockbuster drug relugolix, which won Food and Drug Administration approval this month as the first oral hormone therapy for men with advanced prostate cancer. Myovant's stock climbed as high as $30.90 per share M onday — a new 52-week… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 28, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

With potential $4 billion Pfizer deal, 'upside-down' Peninsula biotech on hunt for more drugs
Myovant Sciences Ltd. will use the financial muscle generated by a potential $4.2 billion deal with drug giant Pfizer Inc. to beef up its pipeline of cancer and women's health drugs. The Pfizer compact, disclosed Monday, centers on Brisbane-based Myovant's potential blockbuster drug relugolix, which won Food and Drug Administration approval this month as the first oral hormone therapy for men with advanced prostate cancer. Myovant's stock climbed as high as $30.90 per share M onday — a new 52-week… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 28, 2020 Category: American Health Authors: Ron Leuty Source Type: news

Jaw Necrosis Risk in Cancer Patients on Zoledronic Acid Varies With Dosing Jaw Necrosis Risk in Cancer Patients on Zoledronic Acid Varies With Dosing
In patients treated with zoledronic acid for bone metastases, the risk of osteonecrosis of the jaw was associated with cancer type, oral health and dosing frequency, researchers found in a recent study.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - December 28, 2020 Category: Orthopaedics Tags: Dental & Oral Health News Source Type: news

What Do Early Stages of Mouth Cancer Look Like
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - December 28, 2020 Category: General Medicine Source Type: news

Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Company to Host Investor Conference Call Today at 8:30AM EST PRINCETON, N.J., Dec. 22, 2020 -- (Healthcare Sales & Marketing Network) -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on develo... Biopharmaceuticals, Oncology Soligenix, dusquetide, oral mucositis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 22, 2020 Category: Pharmaceuticals Source Type: news

New oral hormone drug for prostate cancer
The Food and Drug Administration has approved the use of a new oral hormone therapy drug, Relugolix, for treating advanced prostate cancer in men.Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - December 22, 2020 Category: Endocrinology Source Type: news

FDA Approves First Oral Hormone Therapy for Advanced Prostate Cancer
MONDAY, Dec. 21, 2020 -- Orgovyx (relugolix) is now approved to treat advanced prostate cancer and is the first oral hormone therapy approved for this indication, the U.S. Food and Drug Administration announced Friday. As opposed to currently... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 21, 2020 Category: Pharmaceuticals Source Type: news

Oral Contraceptives Protect Against Ovarian, Endometrial Cancer
Increased risk for breast cancer observed, which was seen for up to two years after discontinuation of oral contraceptives (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 21, 2020 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Journal, Source Type: news

Oral Contraceptives Protect Against Ovarian, Endometrial Cancer
MONDAY, Dec. 21, 2020 -- Oral contraceptives have a lasting protective effect against ovarian and endometrial cancer, according to a study published online Dec. 17 in Cancer Research. Torgny Karlsson, Ph.D., from Uppsala University in Sweden, and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 21, 2020 Category: Pharmaceuticals Source Type: news

FDA OKs First Oral Hormone Tx for Advanced Prostate Cancer FDA OKs First Oral Hormone Tx for Advanced Prostate Cancer
Relugolix is an oral form of androgen deprivation therapyFDA Approvals (Source: Medscape Urology Headlines)
Source: Medscape Urology Headlines - December 18, 2020 Category: Urology & Nephrology Tags: Hematology-Oncology News Source Type: news

FDA Approves Orgovyx (relugolix) as the First Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer
BASEL, Switzerland, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that the U.S. Food and Drug Administration (FDA) has approved Orgovyx... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 18, 2020 Category: Drugs & Pharmacology Source Type: news

FDA Approves First Oral Hormone Therapy for Treating Advanced Prostate Cancer
Today, the FDA approved the first oral hormone therapy for treating advanced prostate cancer. This therapy may eliminate some patients ’ need to visit the clinic for treatments that require administration by a health care provider. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 18, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves relugolix for advanced prostate cancer
On December 18, 2020, the Food and Drug Administration approved the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist, relugolix, (ORGOVYX, Myovant Sciences, Inc.) for adult patients with advanced prostate cancer. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 18, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Top Global Health Moments of 2020
By The Editorial Team, IntraHealth International Community Health Nurse Olivia Yeboah thoroughly washes her hands at the Akropong Clinic in Ghana. Photo by Emmanuel Attramah, PMI Impact Malaria/US President's Malaria Initiative.December 17, 2020If we wanted to, we could list a COVID-19 moment for every month of 2020.  We all know that the onset of the coronavirus pandemic—first in China and then worldwide—overwhelmed news coverage this year. And with good reason. It’s the first large-scale global pandemic in 100 years. At the time this article was publ...
Source: IntraHealth International - December 17, 2020 Category: International Medicine & Public Health Authors: kseaton Tags: HIV & AIDS COVID-19 Nutrition Policy Advocacy Health Workforce Systems Nursing Midwifery 2020 Health Workers Source Type: news

Oral contraceptive pills protect against ovarian and endometrial cancer
(Uppsala University) A comprehensive study from Uppsala University, involving more than 250,000 women, shows that oral contraceptive use protects against ovarian and endometrial cancer. The protective effect remains for several decades after discontinuing the use. The study is published in the journal Cancer Research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 17, 2020 Category: Cancer & Oncology Source Type: news

A Disappointment in Triple-Negative Breast Cancer A Disappointment in Triple-Negative Breast Cancer
The oral AKT inhibitor ipatasertib does not seem to offer any clinical benefit when added to paclitaxel for women with gene-altered advanced triple- negative breast cancer, indicate phase 3 trial data.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 16, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Oral Microbiome Tied to Lung Cancer Risk in Never - Smokers
Risk varies according to profile of the oral microbiota; risk lower with greater abundance of Spirochaetia, Bacteroidetes (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 15, 2020 Category: Cancer & Oncology Tags: Oncology, Pathology, Pulmonology, Journal, Source Type: news

Oral Microbiome Tied to Lung Cancer Risk in Never-Smokers
TUESDAY, Dec. 15, 2020 -- Lower alpha diversity of the oral microbiota is associated with an increased risk for lung cancer among never-smokers, and the abundance of specific taxa are associated with altered risk, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 15, 2020 Category: Pharmaceuticals Source Type: news

What Are Potential Complications of Breast Surgery?
Discussion Common reasons for seeing a breast surgeon would include management of benign or malignant masses with or without breast reconstruction, breast augmentation, and other reasons can be infection or trauma that need surgical treatment. The breast is formed starting around the 6th week of gestation by breast buds along the mammary line. Breasts then develop from the downgrowth of epithelia into the mesenchymal tissue, which continues to grow. Around 8-9 months a pit forms as entry into the lactiferous ducts. “Nipple inversion is caused either by failure of the lactiferous ducts to develop and grow during matur...
Source: PediatricEducation.org - December 14, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Pregnancy is safe for breast cancer survivors
Most breast cancer survivors who get pregnant have good outcomes and deliver...Read more on AuntMinnie.comRelated Reading: Skipping rad therapy may not hinder breast cancer survival Imaging detects big, rare tumor protruding from fetus's mouth Ultrasound vs. mammo: What's best for lactating women? CT details effect of COVID-19 on pregnant women More pregnant women are undergoing imaging (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 10, 2020 Category: Radiology Source Type: news

New Data Demonstrate Long-Term Benefit of IMBRUVICA ® (ibrutinib) as First-Line Treatment for High-Risk Chronic Lymphocytic Leukemia
This study highlighted the need for cytogenetic/molecular testing before CIT treatment, consistent with clinical treatment guidelines.[8],[9]Real-World Prognostic Biomarker Testing, Treatment Patterns, And Dosing Among Patients With CLL/SLL From the informCLL™ Prospective Observational Registry (Abstract #547)An oral presentation on Monday, December 7, will feature results from the informCLL™ real-world prospective observational registry assessing treatment patterns in the era of novel agents.4 Key Study Findings:· The most common index treatment was IMBRUVICA®; the majority of patients treated with ...
Source: Johnson and Johnson - December 6, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents First Data from the Phase 1 Study of the GPRC5DxCD3 Bispecific Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma
December 5, 2020 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today initial data for the Phase 1 first-in-human dose escalation study of talquetamab (JNJ-64407564) for the treatment of relapsed or refractory multiple myeloma (NCT03399799). Talquetamab is a first-in-class, and the only investigational bispecific antibody that targets both GPRC5D, a novel multiple myeloma target, and CD3 on T-cells. Initial results for both the subcutaneous (SC) and intravenous (IV) formulations show encouraging clinical activity against the GPRC5D target, which is highly expressed on multip...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Updated Results from the Phase 1 Study of the BCMAxCD3 Bispecific Teclistamab Show Preliminary Efficacy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
This study evaluated the ability of teclistamab to induce cytotoxicity and T-cell activation.About TeclistamabTeclistamab is an investigational bispecific antibody targeting both BCMA and CD3. BCMA, B-cell maturation antigen, is expressed at high levels on multiple myeloma cells.[3],[4],[5],[6],[7] Teclistamab redirects CD3-positive T-cells to BCMA-expressing myeloma cells to induce cytotoxicity of the targeted cells.5,6 Results from preclinical studies demonstrate that teclistamab kills myeloma cell lines and bone marrow-derived myeloma cells from heavily pretreated patients.6 Teclistamab is currently being evaluated in a...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Early, Deep, Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) Observed in Phase 1b/2 CARTITUDE-1 Study Show Potential of BCMA CAR-T in Treatment of Heavily Pretreated Patients with Multiple Myeloma
December 5, 2020 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today longer-term results from the combined Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of ciltacabtagene autoleucel (cilta-cel), an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma. These data, presented as an oral presentation at the American Society of Hematology (ASH) 2020 Annual Meeting (Abstract #177), continued to demonstrate a very hig...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Disease-Free Survival Data from CAPTIVATE Study Demonstrate Benefit of IMBRUVICA ® (ibrutinib)-Based Regimen as Fixed Duration, First-Line Treatment for Patients with Chronic Lymphocytic Leukemia
December 5, 2020 (RARITAN, N.J.) – New data from the Phase 2 CAPTIVATE study were presented today during an oral session at the 2020 American Society of Hematology (ASH) Annual Meeting (Abstract #123). The study evaluated the efficacy and safety of IMBRUVICA® (ibrutinib) plus venetoclax in the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and showed that, after achieving undetectable minimal residual disease (uMRD) in both the blood and bone marrow with the IMBRUVICA® combination regimen, the one-year disease-free survival (DFS) of patients randomized ...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Venetoclax added to standard treatments shows promise in high-risk myeloid blood cancers
(Dana-Farber Cancer Institute) The novel oral drug venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers and in early studies the combination shows promise of improved outcomes, say scientists from Dana-Farber Cancer Institute. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 5, 2020 Category: International Medicine & Public Health Source Type: news

Cancer warning: Seven symptoms of a deadly tumour in your mouth that you may be missing
CANCER symptoms may be difficult to spot, as they could easily be mistaken for something less serious. These are the warning signs of a deadly tumour in your mouth that you should be aware of, including having an ulcer that doesn't heal, or difficulty swallowing. (Source: Daily Express - Health)
Source: Daily Express - Health - December 5, 2020 Category: Consumer Health News Source Type: news

NIDCR's Winter 2020 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Winter 2020 E-Newsletter In this issue: NIDCR News Funding Opportunities NIH/HHS News Funding Notices Science Advances Subscribe to NICDR News Grantee News   NIDCR News NIDCR Welcomes New Director Rena D’Souza Rena N. D’Souza, DDS, MS, PhD, was sworn in as the director of NIDCR by NIH Director Francis S. Collins, MD, PhD, on October 13. Prior to joining NIH, Dr. D’Souza was the assistant vice president for academic affairs and education for health s...
Source: NIDCR Science News - December 4, 2020 Category: Dentistry Source Type: news

& #946;-AR agonist therapy puts the brakes on oral cancer progression
(Tokyo Medical and Dental University) Oral cancer has a high mortality rate that is mainly attributed to metastasis. Researchers from Tokyo Medical and Dental University (TMDU) screened a panel of small chemical compounds for their ability to inhibit metastasis in oral cancer, identifyingβ2?AR-agonist isoxsuprine as a potential candidate. Treatment of various oral cancer cells with isoxsuprine suppressed their motility, while tumor size was significantly decreased in isoxsuprine-treated mice, suggesting thatβ-AR-agonist therapy could be an effective new treatment for oral cancer. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - December 3, 2020 Category: International Medicine & Public Health Source Type: news